Abstract Topics
Submit Your Abstract
Travel Grant and Participation Award

 

 

ESPID 2027 Abstract Submission Guidelines

Participants interested in presenting their abstract at the ESPID 2027 Annual Meeting are invited to submit their original research via the online abstract submission portal. All submissions will undergo peer review by the Scientific Programme Committee.

Key Dates

Abstract Submission Opens13 October 2026
Abstract Submission DeadlineTuesday, 19 January 2027 midnight CET (23:59)
Abstract Notifications*End February 2027
Late-Breaking Submission Opens16 March 2027
Late-Breaking Abstract Submission deadline30 March 2027 (23:59, CEST) 
Late-Breaking Abstract Notifications*Mid-End April 2027
 

*All notification dates are subject to minor adjustments. Updates will be posted on the website.

 
Abstract Preferences & Formats
1. Abstract Type

  • Type 1: Regular Abstract

  • Type 2: Case Report / Case Series

  • Type 3: Walter Marget Workshop

2. Presentation Preferences

  • Parallel Symposium: Consideration for oral presentation within a parallel session.

  • Oral Presentation / Poster Discussion: Consideration for oral sessions or E-Poster Discussion sessions.

  • E-Poster Viewing: Displayed in the digital E-Poster gallery.

  • NEW! Science Slam: (Optional additional opportunity — see below).

NEW: Science Slam Format

The Science Slam is a high-energy, creative session running in addition to regular scientific oral/poster presentations.

  • The Concept: Think TED-talk meets short elevator pitch! Channel your inner “influencer” to present your findings in a memorable, extraordinary way.

  • Creative Freedom: Use props, costumes, storytelling, poetry, or music—let your imagination fly.

  • Format: Maximum 5 minutes per pitch.

  • How to Apply: Check the Science Slam opt-in box during abstract submission. Indicating interest does not affect your eligibility for standard scientific sessions. Up to 10 submitters will be selected to present live!

  • Online Only: Abstracts must be submitted exclusively through the online portal. Emailed or faxed submissions will not be reviewed.

  • Deadlines: Late submissions will not be considered.

  • Presenter Limits & Registration:

    • An individual may serve as the presenting author for a maximum of 5 abstracts.

    • The presenting author must register and pay to attend ESPID 2027.

  • Originality & Publication: Abstracts must be original and not previously published or presented at another international meeting prior to ESPID 2027. Accepted abstracts will be published open-access by ESPID for a minimum of 5 years.

  • Language: All abstracts must be submitted in clear English.

  • Data Requirement: Abstracts stating “data will be discussed during the presentation” will be rejected.

  • Conflicts of Interest: All submitters must disclose relevant financial relationships/conflicts of interest in the submission form.

  • Presenting Author Details: Full name, affiliation (institution, city, country), and email address (all correspondence will be sent here).

  • Abstract Title: Maximum 25 words (UPPER CASE).

  • Abstract Body Text: Maximum 280 words (including acknowledgments).

  • Tables & Figures:

    • Maximum 1 table or figure per abstract.

    • Maximum file size: 500 KB | Max dimensions: 600(w) x 800(h) px.

    • Allowed formats: JPEG, GIF, PNG.

  • Formatting Rules:

    • Use standard abbreviations and generic drug names.

    • Avoid commercial or promotional language.

    • Do not include patient names, hospital IDs, or identifying personal data.

  • Drafts: Submissions can be saved as a draft and edited until the submission deadline. Unsubmitted drafts will be deleted after the deadline.

Enhance your abstract before submitting! Use the ESPID AI Abstract Assistant tool within the submission portal to receive automated, intelligent feedback, grammar checks, and structural suggestions prior to final submission.

By submitting an abstract, you confirm and warrant that:

  • You have reviewed the content and all co-authors have approved the submission.

  • You grant ESPID and Kenes Group a non-exclusive, royalty-free, perpetual license to publish, display, and distribute the abstract across official meeting media.

  • The content does not infringe upon third-party rights or intellectual property.

  • You accept that the Scientific Committee reserves the right to make final session and topic allocations.